3 More of The Steadiest Shares That You Can Buy Today: GlaxoSmithKline plc, Reckitt Benckiser Group Plc And SABMiller plc

GlaxoSmithKline plc (LON:GSK), Reckitt Benckiser Group Plc (LON:RB) and SABMiller plc (LON:SAB) are three of the most solid FTSE 100 companies that you can buy shares in.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) sells products that its customers cannot live without. This brings a high degree of visibility to its earnings and profits. Even better, it is difficult for competitors to enter such a highly regulated industry. The result is large and reliable profits and dividends.

Glaxo has been increasing its dividend payout year-on-year for more than a decade. Last year, Glaxo paid 74p of dividends, equal to a 4.4% dividend yield at today’s price.

Earnings and dividend growth is forecast for this year and next. That puts the shares on a prospective P/E for 2014 of 13.2, with an expected yield of 4.9%.

While that may not sound cheap, a company of Glaxo’s quality rarely is.

SABMiller

Super-brewer SABMiller (LSE: SAB)(NASDAQOTH: SBMRY.US) is the company behind Grolsch, Peroni, Pilsner Urquell and the eponymous Miller Genuine Draft. In recent times, the company has been making great progress in its biggest market, Latin America. Growth in Africa (ex-South Africa) has also been considerable.

In the last five years, dividends from SAB have increased from $0.58 per share to $1.01 last year. There have been no cuts to the payout in that time. The shares have responded well to this success and are 170% ahead over the period.

Analysts expect SAB to deliver two years of strong dividend and earnings growth. That puts the shares on a P/E of 17.1 for 2015, with an anticipated yield of 2.5%.

Reckitt Benckiser Group

Reckitt Benckiser Group (LSE: RB) is probably the FTSE 100’s best example of a brand-led business. The company sells leading brand domestic products such as Calgon, Harpic and Nurofen. The company spends heavily on advertising these products. This makes it harder for any other firm to bring out a rival. Thanks to its quality products and marketing, RB makes big sales. This brings considerable economies of scale.

In the last five years, RB has increased its earnings per share and dividend per share ever year. The average rate of earnings increase in that time is 16.3%. Dividend growth has been even higher at an average of 19.3% a year.

Growth is expected to be less in future. The shares today trade on a 2013 P/E of 16.9.

If you are looking for solid shares, get the latest Motley Fool report “5 Shares To Retire On” . This detailed research from our team of expert analysts is entirely free and will be delivered to your inbox immediately. Just click here to start reading now.

> David does not own shares in any of the above companies. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Dividend Shares

2 infrastructure dividend shares with yields of 7% or higher

Jon Smith outlines two dividend shares from a sector that boasts high yields at the moment -- but there are…

Read more »

Investing Articles

2 FTSE 100 growth shares that could shine in 2025

Paul Summers picks out two FTSE 100 growth shares that, despite performing very differently in 2024, he thinks could end…

Read more »

Investing Articles

My top 2 stock market predictions for 2025

This writer didn’t receive a crystal ball for Christmas, but he still has a couple of stock market predictions for…

Read more »

Investing Articles

3 companies that could emulate Nvidia stock’s success in 2025

Nvidia stock has generated market topping growth over the past two years. But investors need to be asking themselves, who…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s my plan for maximising the returns from my Stocks and Shares ISA in 2025

After a good 2024, Stephen Wright has two key ideas he wants to implement in his Stocks and Shares ISA…

Read more »

Investing Articles

3 key FTSE 100 stock updates to watch for in January

My 2025 investing focus is on key FTSE 100 stocks in key sectors, and we won't have very long to…

Read more »

Investing Articles

Why the Diageo share price fell 10% in 2024

The Diageo share price fell 10% last year. But Stephen Wright thinks the stock market's being too pessimistic about a…

Read more »

White female supervisor working at an oil rig
Investing Articles

Why the BP share price fell 16% in 2024

Oil prices have been falling since April causing BP shares to do the same. But Stephen Wright thinks there’s much…

Read more »